NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer


Episode Artwork
1.0x
0% played 00:00 00:00
Sep 14 2024 3 mins   1
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.